Isolation of muscle satellite cells

IL330736APending Publication Date: 2026-09-01THE BRIGHAM & WOMEN S HOSPITAL INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
IL330736
Authority / Receiving Office
IL · IL
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-01-17
Filing Date
2025-01-17
Publication Date
2026-09-01

AI Technical Summary

Technical Problem

Current methods for isolating muscle satellite cells (SCs) are inefficient and complicate production for clinical use due to the low yield of functional SCs, loss of regenerative properties in vitro, and the need for complex purification steps like FACS or magnetic beads-based sorting.

Method used

A filtration/sorting method to obtain a significantly enriched population of INFRA cells, defined by PAX7+ and PDGFRA- expression, involving the generation of myogenic cultures from pluripotent stem cells, mechanical removal of the upper layer, and further purification by flow cytometry using specific antibodies.

Benefits of technology

The method achieves a substantially homogeneous population of functional SCs with at least 70% PAX7+ and PDGFRA-, maintaining their regenerative properties, suitable for clinical applications without stress or modification.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000041_0000
    Figure 00000041_0000
  • Figure 00000041_0001
    Figure 00000041_0001
  • Figure 00000041_0002
    Figure 00000041_0002
Patent Text Reader

Abstract

A composition of INFRA cells is described. The composition includes human muscle stem cells (SCs) expressing the transcription factor PAX7 and lacking the expression of the transmembrane receptor PDGFRA, wherein at least 70% of the population of human muscle SCs are PAX7+ and PDGFRA-. Methods of preparing the INFRA cell compositions, and methods of using the INFRA cells to treat muscle injury are also described.
Need to check novelty before this filing date? Find Prior Art